Alkem Laboratories Ltd.

ALKEM NSE Healthcare Pharmaceuticals
Nifty 200 Nifty 500 Midcap 50 Midcap 100 Midcap 150 LargeMid 250 F&O
₹5,087.50
-0.98%
Delayed · cached 15 min

Fair value analysis

ALKEM
Alkem Laboratories Ltd.
HealthcarePharmaceuticals
₹5,138.00
Close used for this calculation
₹4,532.26Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
61/100
Profitability23/25
Returns10/25
Balance Sheet19/25
Efficiency9/25
Growth15/25
Good
Quality radar
61Prof.23/25Ret.10/25Eff.9/25B.Sht19/25Growth15/25

Consensus fair value

₹4,532.26
Near FV
▼ -11.8% against the close used
Model range ₹2,233.82 – ₹8,669.83
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹2,233.82Fair value₹4,532.26Bull₹8,669.83
FairClose
52-week traded range
52W low ₹5,138.0052W high ₹5,890.00

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Alkem Laboratories Ltd. closed at ₹5,138.00, 13.4% above the consensus fair value of ₹4,532.26 drawn from 10 valuation models.

Financial DNA score 61/100 — Good. P/E of 26.8x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₹2,474.62
-51.8%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₹2,233.82
-56.5%
√(22.5 × EPS × BVPS)
EPS=192.51, BVPS=1152.02 · outside Graham range (P/E 26.8, P/B 4.5) — asset-light, treat as a rough floor
Graham Formula
₹8,669.83
+68.7%
EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate
g=20%, FD=7%
P/E Fair Value
₹6,872.61
+33.8%
EPS × 35.7x (sector P/E)
EPS=192.51, Sector P/E=35.7x
Peter Lynch (PEG)
₹4,812.75
-6.3%
EPS × Growth% (PEG = 1 is fair)
EPS=192.51, g=25%
EV/EBITDA
₹4,979.71
-3.1%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=33.89B
Dividend Discount (DDM)
₹2,885.50
-43.8%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=53.44, r=10%, g=8%
Book Value (P/B)
₹3,715.26
-27.7%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=1152.02, ROE=18.9%, g=6%, r=10%
Reverse DCF
₹5,138.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 11% | Historical: 25%
Margin of Safety
₹3,797.04
-26.1%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=5062.72, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.